Show simple item record

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

dc.contributor.authorSimpson, C R
dc.contributor.authorShi, T
dc.contributor.authorVasileiou, E
dc.contributor.authorKatikireddi, S V
dc.contributor.authorKerr, S
dc.contributor.authorMoore, E
dc.contributor.authorMcCowan, C
dc.contributor.authorAgrawal, U
dc.contributor.authorShah, S A
dc.contributor.authorRitchie, L D
dc.contributor.authorMurray, J
dc.contributor.authorPan, J
dc.contributor.authorBradley, D T
dc.contributor.authorStock, S J
dc.contributor.authorWood, R
dc.contributor.authorChuter, A
dc.contributor.authorBeggs, J
dc.contributor.authorStagg, H R
dc.contributor.authorJoy, M
dc.contributor.authorTsang, R S M
dc.contributor.authorde Lusignan, S
dc.contributor.authorHobbs, R
dc.contributor.authorLyons, R A
dc.contributor.authorTorabi, F
dc.contributor.authorBedston, S
dc.contributor.authorO'Leary, M
dc.contributor.authorAkbari, A
dc.contributor.authorMcMenamin, J
dc.contributor.authorRobertson, C
dc.contributor.authorSheikh, A
dc.date.accessioned2021-09-16T11:56:01Z
dc.date.available2021-09-16T11:56:01Z
dc.date.issued2021-07
dc.identifier200471382
dc.identifier49bdc1e6-6543-47bf-81b5-56488c0cc711
dc.identifier34108714
dc.identifier85107519071
dc.identifier000659384400001
dc.identifier.citationSimpson , C R , Shi , T , Vasileiou , E , Katikireddi , S V , Kerr , S , Moore , E , McCowan , C , Agrawal , U , Shah , S A , Ritchie , L D , Murray , J , Pan , J , Bradley , D T , Stock , S J , Wood , R , Chuter , A , Beggs , J , Stagg , H R , Joy , M , Tsang , R S M , de Lusignan , S , Hobbs , R , Lyons , R A , Torabi , F , Bedston , S , O'Leary , M , Akbari , A , McMenamin , J , Robertson , C & Sheikh , A 2021 , ' First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland ' , Nature Medicine , vol. 27 , pp. 1290-1297 . https://doi.org/10.1038/s41591-021-01408-4en
dc.identifier.issn1078-8956
dc.identifier.otherPubMedCentral: PMC8282499
dc.identifier.urihttps://hdl.handle.net/2164/17089
dc.descriptionEAVE II is funded by the Medical Research Council (MC_PC_19075) with the support of BREATHE: the Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and the Community Health and Social Care Directorate of the Scottish Government. R.H. acknowledges support from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford and the NIHR Oxford BREATHE Centre. We thank D. Kelly from Albasoft Limited for support with making primary care data available and J. Pickett, W. Inglis-Humphrey, V. Hammersley, M. Georgiou, L. Brook and L. Gonzalez Rienda for support with project management and administration. We thank the EAVE II Public Advisory Group. Our thanks to J. Quint, R. Al-Shahi Salman and Q. Hill for their help with reviewing code lists. Our thanks also to G. Schiff and L. Smeeth for reviewing this work before submission to the UK’s Medicines & Healthcare products Regulatory Agency. Data availability A data dictionary covering the datasets used in this study can be found at https://github.com/ EAVE-II/EAVE-II- data-dictionary. The data that support the findings of this study are not publicly available because they are based on de-identified national clinical records. These are, however, available by application via Scotland’s National Safe Haven from Public Health Scotland. The data used in this study can be accessed by researchers through NHS Scotland’s Public Benefit and Privacy Panel via its Electronic Data Research and Innovation Service49. Code availability All code used in this study is publicly available at https://github.com/ EAVE-II/Covid- vaccine-safety-haemo.en
dc.format.extent8
dc.format.extent2758734
dc.language.isoeng
dc.relation.ispartofNature Medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCOVID-19/prevention & controlen
dc.subjectCOVID-19 Vaccines/therapeutic useen
dc.subjectCase-Control Studiesen
dc.subjectCohort Studiesen
dc.subjectFemaleen
dc.subjectHemorrhage/epidemiologyen
dc.subjectHumansen
dc.subjectIncidenceen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectPurpura, Thrombocytopenic, Idiopathic/epidemiologyen
dc.subjectSARS-CoV-2en
dc.subjectScotland/epidemiologyen
dc.subjectSinus Thrombosis, Intracranial/epidemiologyen
dc.subjectThrombocytopenia/epidemiologyen
dc.subjectThromboembolism/epidemiologyen
dc.subjectVenous Thromboembolism/epidemiologyen
dc.subjectYoung Adulten
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectMC_PC_19075en
dc.subject.lccRen
dc.titleFirst-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotlanden
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1038/s41591-021-01408-4
dc.identifier.vol27en


Files in this item

Thumbnail
Name:
Simpson_etal_NM_First_Dose_ChA ...
Size:
2.630Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record